Skip to main content
Retevmo selpercatinib Home
  • Prescribing Information
  • Patient Prescribing Information
Menu closed
Retevmo selpercatinib Home
  • Prescribing Information
  • Patient Prescribing Information
Globe Loading... Reveal available languages
  • House For Patients
    • Understanding Biomarker Testing
    • How Retevmo Works
    • Retevmo in NSCLC
    • Retevmo in Thyroid Cancer
    • Retevmo in Other Cancers
    • Taking Retevmo
    • Savings & Support Resources
      • Savings Information
      • Filling Your Prescription
      • Connect with Others
    • Patient Story
    • Pricing Information
  • For Healthcare Providers
    • Safety & Tolerability
    • Dosing
    • Savings & Support
Ask Lilly

We're here to help.

Phone Call:
1-800-LillyRx
(1-800-545-5979)
Expand contact lilly
Information

To continue using a Savings Card in 2025, eligible patients can download now under the Savings & Support Page.

Savings & Support Resources

See how you may be able to save on Retevmo and get support along the way

Retevmo patients
Retevmo savings card

Retevmo Savings Card

Eligible commercially insured covered patients pay as little as $0 a month*

*Month is defined as 30 days.

Governmental beneficiaries excluded, terms and conditions apply.

Paying for treatment shouldn’t be an additional concern for you and your loved ones, so we’ve created the Retevmo Savings Card, which may help you manage treatment costs.

Need a Savings Card?

Download Savings Card

By enrolling in and using the Retevmo Savings Card Program (“Program”) and using the Retevmo Savings Card (“Card”), you attest that you meet the eligibility criteria, and you agree to comply with the terms and conditions described below:

Card Eligibility:

  1. You have been prescribed Retevmo® (selpercatinib) for an approved use consistent with FDA-approved product labeling;
  2. You are enrolled in a commercial drug insurance plan and have coverage for Retevmo:
  3. You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program;
  4. You are a resident of the United States or Puerto Rico; and
  5. You are 18 years of age or older.

Card Terms and Conditions
For patients with commercial drug insurance coverage for Retevmo: You must have commercial drug insurance that covers Retevmo and a prescription for an approved use consistent with FDA-approved product labeling to pay as little as $0 for a 1-month prescription fill of Retevmo. Month is defined as 30-days. Card savings are subject to a maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and separate maximum annual savings of up to $9,200 per calendar year. Card may be used for a maximum of up to 14 prescription fills per calendar year. Except where prohibited by applicable state law, Card monthly and annual savings are reduced if Lilly identifies that you are enrolled in a plan or program, sometimes called a maximizer plan, that adjusts your cost sharing amount to be equal to or include some portion of the savings provided by the Card and attempts to prevent the savings from this Card from being applied to your out-of-pocket costs, including but not limited to copayments, coinsurances, and deductibles (“Maximizer”). If the Program identifies you are enrolled in a Maximizer, Card savings are reduced to a maximum monthly savings of up to $25 and a separate maximum annual savings of up to $350 per calendar year. If you have reason to believe that the Program erroneously identified enrollment in a Maximizer, please call the Retevmo Savings Card Program at 1-866-615-3716. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2025.

Additional Program Terms and Conditions
If you have an insurance plan that is participating in an alternate funding program (“AFP”) that requires you to apply to the Retevmo Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of Retevmo, you are not eligible for and are prohibited from using the Retevmo Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member’s use of Retevmo Savings Card Program. You agree to inform the Retevmo Savings Card Program if you are or become a member of such an alternative funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum Card savings. Monthly and annual maximum savings are set at Lilly’s sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for Retevmo, only allows partial coverage for Retevmo, removes coverage for Retevmo and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of Retevmo, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for Retevmo. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving drug coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the Retevmo Savings Card and agree to call the Retevmo Savings Card Program at 1-866-615-3716 to stop participation. Card activation is required. You may not seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving Retevmo. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are nontransferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. THIS CARD IS NOT INSURANCE. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Lilly’s sole discretion to terminate, rescind, revoke, or amend Card eligibility and/or Card terms and conditions includes the right to terminate any individual Card if Lilly determines, in its sole discretion, that a patient does not satisfy the Card’s eligibility criteria or is using or has attempted to use the Card inconsistently with these terms and conditions. Eligibility criteria, and terms and conditions for the Retevmo Savings Card Program may change from time to time; the most current version can be found at https://retevmo.lilly.com/savings-support. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly’s right to terminate, rescind, revoke or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2025.

TRICARE® is a registered trademark of the Department of Defense (DoD), DHA.

Filling your prescription

There are multiple ways to get Retevmo, depending on your insurance. You may receive your medication from your hospital, your doctor, or from a specialty pharmacy.

Specialty pharmacy icon

Here’s how a specialty pharmacy works with you to fill your Retevmo prescription:

  • Your doctor sends your prescription to a specialty pharmacy
  • The specialty pharmacy will call you to schedule a date and time to deliver your Retevmo medication (you may not recognize the phone number)
  • The specialty pharmacy can also help assess your eligibility for the Retevmo Savings Card†

†This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program. Terms and conditions apply for eligible patients.

Lilly Support Services™ for Retevmo can help you find the specialty pharmacy with the lowest out-of-pocket cost

Learn more about Retevmo

Brochures on how Retevmo works

See how Retevmo works, how to take it, and some side effects you may experience with treatment. Download the brochure below.

Download the Patient Brochure Download
Share your Retevmo experience for yourself or a loved one

Share your Retevmo experience

If you or a loved one has been treated with Retevmo and you would like to share your story, please call Lilly Support Services™ at 1-800-LillyRx (1-800-545-5979).

Hear a real story from a real patient taking Retevmo

Support groups

Connect with others in your community who understand your diagnosis

You are not alone on this cancer journey. There are organizations that can connect you with opportunities and support.‡

American Lung Association and Lung Force logos

American Lung Association® is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research. The Lung Association is committed to defeating lung cancer and supporting those affected by it.

Go2 Foundation for Lung Cancer logo

GO2 Foundation for Lung Cancer® transforms survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.

The Happy Lungs Project

The Happy Lungs Project is patient driven 501c3 public charity committed to supporting researchers and clinicians in their work toward finding a cure for RET Positive Non-Small Cell Lung Cancer, while providing helpful information to empower patients in their own healing and journey.

Lungevity logo

LUNGevity Foundation®, the nation's leading lung cancer-focused nonprofit, is committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease.

RetPositive logo

Founded by survivors and caregivers of those impacted by RET-driven cancers, RETpositive aims to build hope, resources and a sense of community for RET-positive cancer patients. By sharing emotional support and knowledge of the latest treatment options and current RET specific research, RETpositive hopes to increase both quality of life and life expectancy for those impacted by RET-driven malignancies.

Thanc Foundation logo

The THANC (Thyroid, Head and Neck Cancer) Foundation is an international, independent nonprofit dedicated to supporting research and education in the early detection and treatment of thyroid, head and neck cancers. THANC is actively committed to advancing new therapies and alleviating the suffering and functional impairment of patients who undergo treatment. The THANC Guide is a significant resource that endeavors to help patients through their cancer journey.

ThyCa: Thyroid Cancer Survivors' Association logo

ThyCa: Thyroid Cancer Survivors’ Association, Inc., an international nonprofit organization advised by thyroid cancer specialists, educates and supports patients and families through its comprehensive website, support groups, person-to-person support, free newsletter and downloadable handbooks and low-iodine cookbook, available in numerous languages. ThyCa sponsors seminars, workshops, and an annual international 3-day conference, as well as Thyroid Cancer Awareness Month, year-round awareness programs for early detection, and thyroid cancer research funds and research grants.

‡This information has been provided by the listed organizations, and Lilly is not responsible for the content. Its use on this site is not intended to serve as an endorsement of the listed organizations. All third-party organization names and other trademarks are the property of their respective trademark owners. Those trademark owners are not affiliated with Lilly and they do not sponsor or endorse this material.

Warnings - RETEVMO may cause serious side effects, including:

 

Liver problems: Liver problems (increased liver enzymes) can happen during treatment with RETEVMO and may sometimes be serious. Your healthcare provider will do blood tests before and during treatment with RETEVMO to check for liver problems. Tell your healthcare provider right away if you get any of the following symptoms of liver problems during treatment:

  • yellowing of your skin or the white part of your eyes (jaundice)
  • dark, “tea-colored” urine
  • sleepiness
  • bleeding or bruising
  • loss of appetite
  • nausea or vomiting
  • pain on the upper right side of your stomach area

Lung problems: RETEVMO may cause severe or life-threatening inflammation (swelling) of the lungs during treatment, that can lead to death. Tell your healthcare provider right away if you get any new or worsening lung symptoms, including:

  • shortness of breath
  • cough
  • fever

High blood pressure (hypertension): High blood pressure is common with RETEVMO. It may sometimes be severe. You should check your blood pressure regularly during treatment with RETEVMO. If you develop blood pressure problems, your healthcare provider may prescribe medicine to treat your high blood pressure. Tell your healthcare provider if you have increased blood pressure readings or get any symptoms of high blood pressure, including:

  • confusion
  • headaches
  • shortness of breath
  • dizziness
  • chest pain

Heart rhythm changes (QT prolongation). RETEVMO may cause very slow, very fast, or irregular heartbeats. Your healthcare provider may perform tests before and during treatment with RETEVMO to check the activity of your heart and the levels of body salts (electrolytes) and thyroid-stimulating hormone (TSH) in your blood. Tell your healthcare provider right away if you get any of the following symptoms:

  • loss of consciousness
  • fainting
  • dizziness
  • a change in the way your heart beats (heart palpitations)

Bleeding problems: RETEVMO can cause bleeding, which can be serious and may lead to death. Tell your healthcare provider if you have any signs of bleeding during treatment, including:

  • vomiting blood or if your vomit looks like coffee-grounds
  • pink or brown urine
  • red or black stools that look like tar
  • coughing up blood or blood clots
  • unusual bleeding or bruising of your skin
  • menstrual bleeding that is heavier than normal
  • unusual vaginal bleeding
  • nose bleeds that happen often
  • drowsiness or difficulty being awakened
  • confusion
  • headache
  • change in speech

Allergic reactions: RETEVMO can cause a fever, rash, or pain in muscles or joints, especially during the first month of treatment. Tell your healthcare provider if you get any of these symptoms.

Tumor lysis syndrome (TLS): TLS is caused by a fast breakdown of cancer cells. TLS can cause you to have kidney failure, the need for dialysis treatment, and an abnormal heartbeat. TLS can lead to hospitalization. Your healthcare provider may do blood tests to check you for TLS. You should stay well hydrated during treatment with RETEVMO. Call your healthcare provider or get emergency medical help right away if you develop any of these symptoms during treatment with RETEVMO:

  • nausea
  • vomiting
  • weakness
  • swelling
  • shortness of breath
  • muscle cramps
  • seizures

Risk of wound healing problems: Wounds may not heal well during treatment with RETEVMO. Tell your healthcare provider if you plan to have any surgery before or during treatment with RETEVMO.

  • You should stop taking RETEVMO at least 7 days before planned surgery.
  • Your healthcare provider should tell you when you may start taking RETEVMO again after surgery.

Low thyroid hormone levels in your blood (hypothyroidism). Your healthcare provider will do blood tests to check your thyroid function before and during treatment with RETEVMO. Tell your healthcare provider right away if you develop signs or symptoms of low thyroid hormone levels, including:

  • weight gain
  • feeling cold
  • tiredness that worsens or does not go away
  • constipation

Hip joint problems (slipped capital femoral epiphysis or slipped upper femoral epiphysis) in children. Tell your healthcare provider right away if you develop sign and symptoms of hip problems, including hip or knee pain or a painless limp.

Common side effects

The most common side effects of RETEVMO in adults with solid tumors include:

  • swelling of your arms, legs, hands, and feet (edema)
  • diarrhea
  • tiredness
  • dry mouth
  • stomach-area (abdominal) pain
  • constipation
  • rash
  • nausea
  • headache

The most common side effects of RETEVMO in children 2 years and older with solid tumors include:

  • muscle and bone pain
  • diarrhea
  • headache
  • nausea
  • vomiting
  • coronavirus infection
  • stomach-area (abdominal) pain
  • tiredness
  • fever
  • bleeding

The most common severe abnormal laboratory test results with RETEVMO in adults with solid tumors include decreased white blood cell count, increased liver enzymes, decreased levels of sodium in the blood, and decreased levels of calcium in the blood.

The most common severe abnormal laboratory test results with RETEVMO in children 2 years and older with solid tumors include decreased levels of calcium in the blood, decreased red blood cell count, and decreased white blood cell count.

RETEVMO may affect the ability to have children for both females and males. Talk to your healthcare provider if you want to have children and you are thinking about starting treatment with RETEVMO.

  • RETEVMO can harm your unborn baby. You should not become pregnant during treatment with RETEVMO.
  • If you are able to become pregnant:
    • Your healthcare provider will do a pregnancy test before you start treatment with RETEVMO.
    • You should use effective birth control (contraception) during treatment and for 1 week after your last dose of RETEVMO. Talk to your healthcare provider about birth control methods that may be right for you.
    • Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with RETEVMO.
  • Males with partners who are able to become pregnant should use effective birth control during treatment with RETEVMO and for 1 week after your last dose of RETEVMO.

These are not all the possible side effects with RETEVMO. If you are concerned about side effects, talk to your doctor. Tell your doctor about any side effects you have. You can also report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using

Before taking RETEVMO, tell your healthcare provider about all your medical conditions, including if you:

  • have liver problems
  • have lung or breathing problems other than lung cancer
  • have high blood pressure
  • have heart problems, including a condition called QT prolongation
  • have bleeding problems
  • plan to have surgery. You should stop taking RETEVMO at least 7 days before your planned surgery.
  • are pregnant or plan to become pregnant. See section above for additional information.
  • are breastfeeding or plan to breastfeed. It is not known if RETEVMO passes into your breast milk. Do not breastfeed during treatment with RETEVMO and for 1 week after your last dose.

Also tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RETEVMO may affect the way other medicines work and other medicines may affect how RETEVMO works, and may increase your risk of side effects.

  • During treatment with RETEVMO, you should avoid taking:
    • St. John’s wort,
    • proton-pump inhibitors (PPIs) such as dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole sodium, and rabeprazole,
    • H2 blockers such as famotidine, nizatidine, and cimetidine,
    • antacids that contain aluminum, magnesium, calcium, simethicone, or buffered medicines.

If you cannot avoid taking PPIs, H2 blockers, or antacids, see the “How to take with certain other medicines” section below for more information. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

How to take RETEVMO

  • Take RETEVMO exactly as your healthcare provider tells you.
  • Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with RETEVMO if you have side effects. Do not change your dose or stop taking RETEVMO unless your healthcare provider tells you.
  • Swallow RETEVMO capsules and tablets whole. Do not break, crush, or chew.
  • Do not give RETEVMO capsules to your child if they are unable to swallow a capsule.
  • Take RETEVMO with or without food.
  • If you vomit after taking a dose of RETEVMO, do not take an extra dose. Take the next dose of RETEVMO at your scheduled time.
  • Do not take a missed dose of RETEVMO unless it is more than 6 hours until your next scheduled dose.
  • If you take too much RETEVMO, call your healthcare provider or go to the nearest hospital emergency room right away.

How to take RETEVMO with certain other medicines

  • If you take a PPI (such as dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole sodium, or rabeprazole), take RETEVMO with food.
  • If you take an H2 blocker (such as famotidine, nizatidine, or cimetidine), take RETEVMO 2 hours before or 10 hours after taking the H2 blocker.
  • If you take an antacid that contains aluminum, magnesium, calcium, simethicone, or buffered medicines, take RETEVMO 2 hours before or 2 hours after taking the antacid.

Learn more

RETEVMO is a prescription medicine available as 40 mg and 80 mg capsules, and 40 mg, 80 mg, 120 mg, and 160 mg tablets. For more information, call 1-800-545-5979 or go to www.Retevmo.com.

This summary provides basic information about RETEVMO. It does not include all information known about this medicine. Read the information that comes with your medicine each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other health care provider about RETEVMO and how to take it. Your doctor is the best person to help you decide if RETEVMO is right for you.

SE CON BS ALL 27SEP2024

RETEVMO® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

INDICATIONS AND SAFETY SUMMARY

RETEVMO® (reh-TEHV-moh) is used to treat certain cancers caused by abnormal RET genes in:
  • adults with locally advanced non-small cell lung cancer (NSCLC) or NSCLC that has spread.
  • adults and children 2 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread, who require a medicine by mouth or injection (systemic therapy).
  • adults and children 2 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy), and who have received radioactive iodine and it did not work or is no longer working.
  • adults and children 2 years of age and older with locally advanced solid tumors (cancers) or solid tumors that have spread, and have gotten worse (progressed) on or after other treatment or there are no satisfactory treatment options.*

Your healthcare provider will perform a test to make sure that RETEVMO is right for you.

  • It is not known if RETEVMO is safe and effective when used in children younger than 2 years of age for the treatment of:
    • advanced MTC or MTC that has spread who require a medicine by mouth or injection.
    • advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection, and have received radioactive iodine and it did not work or is no longer working.
    • locally advanced solid tumors or solid tumors that have spread, and have gotten worse on or after other treatment or there are no satisfactory treatment options.
  • in children for other conditions.

* This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to provide additional information about clinical benefit of Retevmo for this use.

  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap
Need assistance?
Call 1-800-545-5979

This site is intended for US residents aged 18 or older.

Retevmo® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Lilly Support Services™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

PP-SE-US-0993 03/2025 ©Lilly USA, LLC 2025. All rights reserved.

Your Privacy Choices

Cookie Settings

Terms of Use Privacy Statement Consumer Health Privacy Notice Accessibility Statement Sitemap
Lilly logo